Progress of NRF2 Signaling Pathway in Promoting Proliferation
of Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.37
- Author:
Yixuan FANG
1
;
Xinru ZOU
1
;
Shuning HU
1
;
Lili JI
1
Author Information
1. Department of Pathological Anatomy, School of Medicine, Nantong University, Nantong 226001, China.
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
NRF2;
Proliferation
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
NF-E2-Related Factor 2/metabolism*;
Lung Neoplasms/pathology*;
Gene Expression Regulation, Neoplastic;
Signal Transduction;
Cell Proliferation
- From:
Chinese Journal of Lung Cancer
2022;25(10):735-741
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity and mortality of lung cancer ranks among the top cancers in the world. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, with limited treatment options and poor prognosis. The nuclear factor E2-related factor 2 (NRF2) signaling pathway is highly mutated and activated in NSCLC, and promotes the malignant progression of lung cancer through various mechanisms. NRF2-targeted therapy will provide new treatment strategies for patients with NSCLC. This article will review the basic structure and response pathways of the NRF2 pathway, the mechanism of NRF2 regulating lung cancer cell proliferation, and the research and development progress of NRF2 inhibitors.
.
